{"entity":{"id":"nct07234162","kind":"trial","name":"A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)","aka":[],"tldr":"A phase 3 trial of Golidocitinib run by Dizal Pharmaceuticals, now recruiting.","summary":"A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19) is a phase 3 interventional study registered as NCT07234162 by Dizal Pharmaceuticals, with 218 participants planned, started 2024-05-13. Conditions listed: Peripheral T-cell Lymphoma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07234162","url":"https://clinicaltrials.gov/study/NCT07234162"}],"tags":["ctgov-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["golidocitinib"],"companies":["dizal"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07234162","phase":"3","setting":"A Phase 3, Open-Label, Randomized, Multinational Study to Investigate the Anti-tumor Efficacy of Golidocitinib Versus Investigator's Choice in Adult Patients With Relapsed/Refractory Peripheral T-cell Lymphoma","sponsor":"Dizal Pharmaceuticals","enrolled":218,"outcomes":[]},"route":"/trials/nct07234162/","neighbours":{"drug":[{"id":"golidocitinib","kind":"drug","name":"Golidocitinib","route":"/drugs/golidocitinib/"}],"company":[{"id":"dizal","kind":"company","name":"Dizal Pharmaceutical","route":"/companies/dizal/"}]}}